Kamada Ltd.
Israeli biopharmaceutical company specialising in plasma-derived protein therapeutics with FDA-approved manufacturing facility in Beit Kama, Israel
Take Action
Apply pressure where it matters. Use these tools and personalise your message with evidence from this page.
- Contact Corporate LeadershipPre-filled letter templates for healthcare industry engagement
- Report New IntelligenceSubmit evidence of contracts, partnerships, or complicity
- Share This ProfileShare on LinkedIn to reach healthcare professionals
- Strategic AnalysisIn-depth analysis and engagement strategy
Before taking action, review our Code of Conduct for professional standards and ethical guidelines.
Help Us Hold Kamada Ltd. Accountable
Your skills and knowledge can strengthen this campaign. Join our volunteer research team or share insider information securely.
Leverage Your Expertise
Do you work in this sector? We need professionals who understand procurement cycles, regulatory compliance, and corporate governance. Don't just boycott - lead!
Decision-Maker Directory
Key individuals with influence over corporate partnerships and procurement decisions. Direct your correspondence to the most relevant role.
Material Risk Framing
Frame your message around business risks. These talking points resonate with corporate stakeholders and institutional investors.
Plasma-derived products subject to strict FDA and EMA regulatory oversight; no documented military applications but specialty nature limits substitution
Dual-listed NASDAQ (KMDA) and Tel Aviv Stock Exchange; strong 2025 financial performance with 17% YoY revenue growth creates investor confidence
B2B biopharmaceutical with minimal public visibility; healthcare necessity and specialty product nature complicates boycott messaging
Specialty plasma-derived therapies with limited global alternatives; FDA-approved Israeli manufacturing creates significant procurement dependency
Strategic Analysis
In-depth assessment of the company's position, vulnerabilities, and recommended approaches for effective engagement.
Lower severity, lower vulnerability — watch list, gather intel
Learn about our methodology — companies are categorised based on severity (harm potential) vs strategic vulnerability (campaign leverage).
Why do these scores change?
Unlike static boycott lists, our targeting model is dynamic. This company's position on the matrix is re-evaluated continually as we verify new contracts, divestments, or policy changes. Your reporting directly impacts this score.
Kamada Ltd. represents a strategic monitoring target as an Israeli-headquartered biopharmaceutical company directly contributing to the apartheid economy through tax revenue and Israeli employment. The company's specialty focus on plasma-derived therapeutics, including critical products like CYTOGAM for transplant patients and KEDRAB for rabies prophylaxis, creates unique boycott complexities due to limited global alternatives and patient care considerations.
Key Leverage Points
- Israeli Economic Contribution: All manufacturing occurs at Israeli facilities (Beit Kama), with corporate taxes and employment directly supporting the Israeli economy
- Institutional Procurement: Hospital systems and government health services make procurement decisions subject to ESG review and ethical sourcing policies
- Investment Pressure: NASDAQ/TASE dual listing enables institutional investor engagement and divestment campaigns
- Distribution Partnerships: Key distribution agreements with partners like Kedrion Biopharma create secondary pressure points
Healthcare Complexity
Kamada's product portfolio presents significant boycott challenges. Plasma-derived immunoglobulins like CYTOGAM (for CMV prophylaxis in transplant patients) and KEDRAB (for rabies post-exposure prophylaxis) serve critical healthcare needs with limited alternatives. The specialty nature of these products, combined with FDA approval requirements and supply chain constraints, means hospital procurement officers face genuine clinical considerations beyond ethical sourcing. Unlike consumer products or commodity pharmaceuticals, plasma-derived therapies require complex manufacturing infrastructure that cannot be easily substituted.
Engagement Strategy
Focus on institutional investor divestment rather than direct procurement pressure given healthcare complexities. Engage pension funds, university endowments, and ethical investment funds holding KMDA positions on ESG grounds. Document Israeli economic contribution through employment figures and tax revenue to support broader economic pressure narratives. For healthcare institutions, emphasise supplier diversification policies and future procurement planning rather than immediate product substitution. Monitor for alternative suppliers entering the plasma-derived therapeutics market that could provide ethical alternatives without patient care compromise.
Evidence & Sources
Verified sources including NGO reports, regulatory filings, and primary documents. Use these to substantiate your correspondence.
Reports $88.8M H1 2025 revenue (11% YoY growth) with 35% profitability increase. Company received Israeli Outstanding Exporter Award 2024 from Ministry of Economy and Industry, presented by the President of Israel.
Open sourceCompany statement confirming manufacturing operations at Israeli Beit Kama facility continue uninterrupted despite regional conflict, ensuring global product availability from Israeli production base.
Open sourceReports record $161M annual revenue (13% YoY growth) and $14.5M net income (75% increase). All manufacturing occurs at Israeli facilities contributing corporate taxes to Israeli economy.
Open sourceThree-year contract awarded for supply of KAMRAB and VARIZIG immune globulin products manufactured at Israeli facilities to Latin American markets.
Open sourceCEO Amir London confirms business continuity in Israel following attacks, states company is 'focused on the well-being of our Israeli employees' while maintaining global supply from Israeli facilities.
Open sourceFIMI Opportunity Funds, Israel's leading private equity firm, became controlling shareholder with 38% stake through $60M private placement, deepening company's integration in Israeli financial ecosystem.
Open sourceOngoing strategic collaboration with Israeli Ministry of Health for production of GMP-standard anti-snake venom serum, demonstrating direct partnership with Israeli government agencies.
Open sourceUpdates & Milestones
- Reaffirms Israeli Operations Continuity
Corporate statement confirms manufacturing at Beit Kama continues despite Middle East events, global supply uninterrupted
- Record Financial Performance
Reports record $161M 2024 revenue and $14.5M net income from Israeli operations, announces $11.5M special dividend
- $25 Million Latin America Contract
Three-year contract awarded for KAMRAB and VARIZIG supply to Latin America, products manufactured at Israeli facilities
- Beit Kama CYTOGAM FDA Approval
FDA approved CYTOGAM manufacturing at Israeli Beit Kama facility, expanding Israeli-based production capacity for US market
- Texas Plasma Collection Expansion
Expanded US plasma collection operations with new Houston, Texas facility in addition to existing Beaumont center
- Israeli Outstanding Exporter Award
Awarded Israeli Outstanding Exporter Award 2024 by Ministry of Economy and Industry, presented by President of Israel, recognising export growth
- Business Continuity Statement Post-October 7
CEO confirms Israeli operations continue uninterrupted, company focused on 'well-being of Israeli employees' while maintaining global supply
- FIMI Becomes Controlling Shareholder
Israel's largest private equity firm FIMI Opportunity Funds acquires 38% stake through $60M private placement, becoming controlling shareholder
- Acquisition of CYTOGAM and VARIZIG
Acquired CYTOGAM, VARIZIG, and WINRHO SDF product lines from Saol Therapeutics, expanding portfolio manufactured at Israeli facilities
- FDA Approval of GLASSIA
First and only liquid, ready-to-use Alpha-1 Antitrypsin product approved by FDA, establishing Kamada as significant Israeli pharmaceutical exporter
- Dual NASDAQ and TASE Listing
Listed on NASDAQ (KMDA) alongside Tel Aviv Stock Exchange, integrating into both US and Israeli financial markets
- Company Founded at Kibbutz Beit Kama
Established in Israel by David Tzur, Ralph Hahn and Kamapharam Ltd. (wholly owned by Kibbutz Beit Kama). First product was human albumin produced at kibbutz facilities.